Seoul National University · Medicine
Professor Do-Youn Oh's research lab focuses on advancing therapeutic strategies for gastrointestinal malignancies, particularly biliary tract cancer (BTC) and pancreatic cancer. The lab investigates the role of immune checkpoint inhibitors, such as durvalumab, in combination with chemotherapy to improve outcomes in advanced disease. A key research direction involves identifying prognostic biomarkers, including sarcopenia and muscle depletion, to better predict patient response and survival. The lab also contributes to pivotal clinical trials, such as the TOPAZ-1 phase 3 study, to establish immunotherapy as a standard of care in BTC.
Figures are computed from collected data and may differ slightly.
BACKGROUND: Patients with advanced biliary tract cancer have a poor prognosis, and first-line standard of care (gemcitabine plus cisplatin) has remained unchanged for more than 10 years. The TOPAZ-1 trial evaluated durvalumab plus chemotherapy for patients with advanced biliary tract cancer. METHODS: In this double-blind, placebo-controlled, phase 3 study, we randomly assigned patients with previously untreated unresectable or metastatic biliary tract cancer or with recurrent disease 1:1 to rece
Sarcopenia at diagnosis and depletion of skeletal muscle, independent of BMI change, during chemotherapy were poor prognostic factors in advanced pancreatic cancer.
378 Background: BTC is a rare, heterogenous cancer with poor prognosis. Reports on immunogenic features of BTC suggest checkpoint inhibition may result in antitumor immune responses, and limited clinical activity has been seen with single agents in advanced settings. Durvalumab (PD-L1 inhibitor) + GemCis showed promising antitumor activity in advanced BTC in a phase 2 study. TOPAZ-1 (NCT03875235) is the first global phase 3 study to evaluate first-line immunotherapy + GemCis in advanced BTC. Met
Open papers in the app to read, cite, and organize with AI.
